Works Cited

1. Worobey M, Gemmel M, Teuwen DE, et al. Direct evidence of extensive diversity of HIV-1 in Kinshasa by 1960. Nature. 2008;455(7213):661-664.

2. Bailes E, Gao F, Bibollet-Ruche F, et al. Hybrid origin of SIV in chimpanzees. Science. 2003;300(5626):1713.

3. Centers for Disease Control and Prevention. HIV-2 infection surveillance—United States, 1987–2009. MMWR. 2011;60(29);985-988.

4. Urden LD, Stacy KM, Lough ME. Critical Care Nursing: Diagnosis and Management. 8th ed. Maryland Heights, MO: Elsevier; 2017.

5. Joint United Nations Programme on HIV/AIDS. The Prevention Gap Report: 2016. Geneva: UNAIDS; 2016. Available at http://www.unaids.org/sites/default/files/media_asset/2016-prevention-gap-report_en.pdf. Last accessed March 3, 2017.

6. U.S. Department of State. U.S. Efforts to Combat the HIV/AIDS Pandemic in Africa: A Special Briefing by Randall Tobias, U.S. Global AIDS Coordinator. Available at http://2001-2009.state.gov/s/gac/rl/rm/47810.htm. Last accessed March 3, 2017.

7. Office of U.S. Global AIDS Coordinator. About PEPFAR. Available at http://www.pepfar.gov/about/index.htm. Last accessed March 3, 2017.

8. U.S. Congress. PEPFAR Stewardship and Oversight Act of 2013. Available at https://www.govtrack.us/congress/bills/113/s1545/text. Last accessed March 3, 2017.

9. Hall HI, An Q, Tang T, et al. Prevalence of diagnosed and undiagnosed HIV infection—United States, 2008–2012. MMWR. 2015;64(24);657-662.

10. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report. Vol. 27: Diagnoses of HIV Infection in the United States and Dependent Areas, 2015. Available at https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-report-2015-vol-27.pdf. Last accessed March 3, 2017.

11. Simon V, Ho DD, Karim Q A. HIV/AIDS epidemiology, pathogenesis, prevention, and treatment. Lancet. 2006;368(9534):489-504.

12. Kahn JO, Walker BD. Acute human immunodeficiency virus type 1 infection. N Engl J Med. 1998;339(1):33-39.

13. U.S. Department of Health and Human Services, Agency for Healthcare Research and Quality. Guide to Clinical Preventive Services, 2014. Available at https://www.ahrq.gov/sites/default/files/wysiwyg/professionals/clinicians-providers/guidelines-recommendations/guide/cpsguide.pdf. Last accessed March 6, 2017.

14. U.S. Preventive Services Task Force. Human Immunodeficiency Virus (HIV) Infection: Screening. Available at https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/human-immunodeficiency-virus-hiv-infection-screening. Last accessed March 6, 2017.

15. Branson BM, Owen SM, Wesolowski LG, et al. Laboratory Testing for the Diagnosis of HIV Infection: Updated Recommendations. Available at https://www.cdc.gov/hiv/pdf/hivtestingalgorithmrecommendation-final.pdf. Last accessed March 6, 2017.

16. Branson BM, Handsfield HH, Lampe MA, et al. H. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006;55(RR14):1-17.

17. Centers for Disease Control and Prevention, Health Resources and Services Administration, National Institutes of Health, American Academy of HIV Medicine, Association of Nurses in AIDS Care, International Association of Providers of AIDS Care, National Minority AIDS Council, Urban Coalition for HIV/AIDS Prevention Services. Recommendations for HIV Prevention with Adults and Adolescents with HIV in the United States, 2014: Summary for Clinical Providers. Rockville, MD: U.S. Department of Health and Human Services; 2014.

18. Centers for Disease Control and Prevention. HIV and Its Transmission. Available at http://www.tdi.texas.gov/pubs/videoresource/fshiv.pdf. Last accessed March 6, 2017.

19. Jin F, Jansson J, Law M, et al. Per-contact probability of HIV transmission in homosexual men in Sydney in the era of HAART. AIDS. 2010;24(6):907-913.

20. Boily MC, Baggaley RF, Wang L, et al. Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. Lancet Infect Dis. 2009;9(2):118-129.

21. Weller SC, Davis-Beaty K. Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst Rev. 2002;1:CD003255.

22. Giannou FK, Tsiara CG, Nikolopoulos GK, et al. Condom effectiveness in reducing heterosexual HIV transmission: a systematic review and meta-analysis of studies on HIV serodiscordant couples. Expert Rev Pharmacoecon Outcomes Res. 2016;16(4):489-499.

23. Smith DK, Herbst JH, Zhang X, Rose CE. Condom effectiveness for HIV prevention by consistency of use among men who have sex with men in the United States. J Acquir Immune Defic Syndr. 2015;68(3):337-344.

24. Millett G, Malebranche D, Mason B, Spikes P. Focusing "down low:" bisexual black men, HIV risk and heterosexual transmission.J Natl Med Assoc. 2005;97(7 Suppl):52S-59S.

25. Centers for Disease Control and Prevention. Oral Sex and HIV Risk. Available at https://www.cdc.gov/hiv/risk/oralsex.html. Last accessed March 6, 2017.

26. Lab Tests Online. HIV Viral Load. Available at https://labtestsonline.org/understanding/analytes/viral-load/tab/test. Last accessed March 6, 2017.

27. Occupational Safety and Health Administration. Occupational Exposure to Bloodborne Pathogens. Section 4: Health Effects. Available at https://www.osha.gov/pls/oshaweb/owadisp.show_document?p_table=PREAMBLES&p_id=806. Last accessed March 6, 2017.

28. Centers for Disease Control and Prevention. HIV transmission through transfusion—Missouri and Colorado, 2008. MMWR. 2010;59(41):1335-1339.

29. Leveton LB, Sox HC Jr, Stoto MA (eds). HIV and the Blood Supply: An Analysis of Crisis Decisionmaking. Washington, DC: National Academies Press; 1995.

30. Centers for Disease Control and Prevention. Frequently Asked Questions: Bloodborne Pathogens—Occupational Exposure. Available at https://www.cdc.gov/oralhealth/infectioncontrol/faq/bloodborne_exposures.htm. Last accessed March 6, 2017.

31. Levesque A, Bruneau J, Jutras-Aswad D, et al. Psychological distress increases needle sharing among cocaine users: results from the COSMO Study. J Addict Res Ther. 2014; S10:003.

32. Siberry GK. Preventing and managing HIV infection in infants, children, and adolescents in the United States. Pediatr Rev. 2014;35(7):268-286.

33. Flynn PM, Abrams EJ. Prevention of Mother-to-Child HIV Transmission in Resource-Limited Settings. Available at http://www.uptodate.com/contents/prevention-of-mother-to-child-hiv-transmission-in-resource-limited-settings. Last accessed March 6, 2017.

34. Centers for Disease Control and Prevention. HIV Among Pregnant Women, Infants, and Children. Available at https://www.cdc.gov/hiv/group/gender/pregnantwomen/index.html. Last accessed March 6, 2017.

35. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. Available at https://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf. Last accessed March 6, 2017.

36. Ahn J, Cohen SM. Transmission of human immunodeficiency virus and hepatitis C virus through liver transplantation. Liver Transpl. 2008;14(11):1603-1608.

37. Centers for Disease Control and Prevention. HIV transmitted from a living organ donor—New York City, 2009. MMWR. 2011;60(10):297-301.

38. Centers for Disease Control and Prevention. Occupational HIV Transmission and Prevention Among Health Care Workers. Available at https://www.cdc.gov/hiv/pdf/workplace/cdc-hiv-healthcareworkers.pdf. Last accessed March 6, 2017.

39. Kuhar DT, Henderson DK, Struble KA, et al. Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis. Infect Control Hosp Epidemiol. 2013;34(9):875-892.

40. Centers for Disease Control and Prevention. Updated Guidelines for Antiretroviral Postexposure Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV—United States, 2016. Available at http://www.cdc.gov/hiv/pdf/programresources/cdc-hiv-npep-guidelines.pdf. Last accessed March 6, 2017.

41. UNAIDS. HIV-Related Opportunistic Diseases: UNAIDS Technical Update. Available at http://data.unaids.org/Publications/IRC-pub05/opportu_en.pdf. Last accessed March 6, 2017.

42. Office of AIDS Research Advisory Council Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Available at https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Last accessed March 6, 2017.

43. U.S. Food and Drug Administration. FDA-Approved HIV Medicines. Available at https://aidsinfo.nih.gov/education-materials/fact-sheets/21/58/fda-approved-hiv-medicines. Last accessed March 6, 2017.

44. U.S. Food and Drug Administration. FDA Approved Novel Antiretroviral Drug. Press Release. Available at https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108960.htm. Last accessed March 6, 2017.

45. U.S. Food and Drug Administration. FDA Approves New Drug to Treat HIV Infection. Available at https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm364744. Last accessed March 6, 2017.

46. U.S. Food and Drug Administration. FDA Approves New HIV Drug: Raltegravir Tablets Used in Combination with Other Antiretroviral Agents. Press Release. Available at https://www.fda.gov/newsevents/newsroom/pressannouncements/2007/ucm109008.htm. Last accessed March 6, 2017.

47. Larson KB, Wang K, Delille C, Otofokun I, Acosta EP. Pharmacokinetic enhancers in HIV therapeutics. Clin Pharmacokinet. 2014;53(10):865-872.

48. INSIGHT START Study Group, Lundgren JD, Babiker AG, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795-807.

49. TEMPRANO ANRS 12136 Study Group, Danel C, Moh R, et al. A Trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med. 2015;373(9):808-822.

50. Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents: Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Available at https://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf. Last accessed March 6, 2017.

51. Luetkemeyer A. HIV InSite Knowledge Base Chapter: Tuberculosis and HIV. Available at http://hivinsite.ucsf.edu/InSite?page=kb-05-01-06. Last accessed March 6, 2017.

52. Centers for Disease Control and Prevention, National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. Treating opportunistic infections among HIV-infected adults and adolescents. MMWR Recomm Rep. 2009;58(RR4):1-207.

53. Kaiser Family Foundation. Women and HIV/AIDS in the United States. Available at http://kff.org/hivaids/fact-sheet/women-and-hivaids-in-the-united-states. Last accessed March 6, 2017.

54. Agency for Health Care Policy and Research. Many People with AIDS Change Their Minds About End-of-Life Care as the Disease Progresses. Available at http://archive.ahrq.gov/research/apr99/ra11.htm. Last accessed March 6, 2017.

55. Heron M. Deaths: leading causes for 2014. Natl Vital Stat Rep. 2016;65(5):1-95.

56. Centers for Disease Control and Prevention. HIV Among Women. Available at http://www.cdc.gov/hiv/group/gender/women/. Last accessed March 6, 2017.

57. Hewitt RG, Parsa N, Gugino L. The Role of Gender in HIV Progression. Available at http://www.medscape.com/viewarticle/410358. Last accessed March 6, 2017.

58. Jarrin I, Geskus R, Bhaskaran K, et al. Gender differences in HIV progression to AIDS and death in industrialized countries: slower disease progression following HIV seroconversion in women. Am J Epidemiol. 2008;168(5):532-540.

59. National Institute of Allergy and Infectious Diseases. NIAID Women's Health Research (FY 2013–Biennial Report for the NIH ORWH Strategic Plan. Available at https://orwh.od.nih.gov/resources/pdf/2-ORWH-ACRWH-Biennial-Report-FY13-14.pdf. Last accessed March 6, 2017.

60. American College of Obstetricians and Gynecologists. Practice Bulletin 117: gynecologic care for women with human immunodeficiency virus. Obstet Gynecol. 2010;116(6):1492-1509.

61. Maini MK, Gilson RJ, Chavda N, et al. Reference ranges and sources of variability of CD4 counts in HIV-seronegative women and men. Genitourin Med. 1996;72:27-31.

62. Heffron R, Donnell D, Rees H, et al. Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. Lancet Infect Dis. 2012;12(1):19-26.

63. Ralph LJ, McCoy SI, Shiu K, Padian NS. Hormonal contraceptive use and women's risk of HIV acquisition: a meta-analysis of observational studies. Lancet Infect Dis. 2015;15(2):181-189.

64. Blackstock OJ, Tate JP, Akgün KM, et al. Sex disparities in overall burden of disease among HIV-infected individuals in the Veterans Affairs healthcare system. J Gen Intern Med. 2013;28(Suppl 2):S577-S582.

65. Centers for Disease Control and Prevention. HIV Among Pregnant Women, Infants, and Children. Available at http://www.cdc.gov/hiv/group/gender/pregnantwomen/index.html. Last accessed March 6, 2017.

66. Centers for Disease Control and Prevention. Revised surveillance case definition for HIV infection—United States, 2014. MMWR. 2014;63(RR3):1-10.

67. Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. Available at https://aidsinfo.nih.gov/contentfiles/lvguidelines/PediatricGuidelines.pdf. Last accessed March 6, 2017.

68. Centers for Disease Control and Prevention. Fact Sheet: HIV/AIDS among Persons Aged 50 and Older. Available at https://www.cdc.gov/hiv/group/age/olderamericans/index.html. Last accessed March 6, 2017.

69. Pilowsky DJ, Wu LT. Sexual risk behaviors and HIV risk among Americans aged 50 years or older: a review. Subst Abuse Rehabil. 2015;6:51-60.

70. U.S. Food and Drug Administration. Truvada for PrEP Fact Sheet: Ensuring Safe a Proper Use. Available at https://www.fda.gov/downloads/NewsEvents/Newsroom/FactSheets/UCM312279.pdf. Last accessed March 6, 2017.

71. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.N Engl J Med. 2010;363:2587-2599.

72. Centers for Disease Control and Prevention. Preexposure Prophylaxis for the Prevention of HIV Infection in the United States, 2014: A Clinical Practice Guideline. Available at https://www.cdc.gov/hiv/pdf/prepguidelines2014.pdf. Last accessed March 6, 2017.

73. U.S. Department of Health and Human Services. What is a Therapeutic HIV Vaccine? Available at https://aidsinfo.nih.gov/education-materials/fact-sheets/19/91/what-is-a-therapeutic-hiv-vaccine-. Last accessed March 6, 2017.

74. International Partnership for Microbicides. What Are Microbicides? Available at http://www.ipmglobal.org/why-microbicides/arv-based-microbicides-and-how-they-work/what-are-microbicides. Last accessed March 6, 2017.

75. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996):1168-1174.

76. Kann L, McManus T, Harris WA, et al. Youth risk behavior surveillance—United States, 2015. MMWR. 2016;65(6):1-174.

77. Breuner CC, Mattson G, American Academy of Pediatrics Committee on Psychosocial Aspects of Child and Family Health. Sexuality education for children and adolescents. Pediatrics. 2016;138(2):e1-e11.

78. Roger AJ, Cambiano V, Brunn T, et al. Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive therapy. JAMA. 2016;316(2):171-181.

79. Washington State Department of Health, Office of Infectious Disease Assessment Unit. Washington State HIV Surveillance Semiannual Report: 2016 Edition. Available at http://www.doh.wa.gov/Portals/1/Documents/Pubs/150-030-HIVSurveillanceSemiAnnualReport1-2016.pdf. Last accessed March 3, 2017.

80. Revised Code of Washington. Chapter 70.24.330 HIV Testing-Consent, Exceptions. Available at http://apps.leg.wa.gov/rcw/default.aspx?cite=70.24.330. Last accessed March 3, 2017.

81. Hanssen I. An intercultural nursing perspective on autonomy. Nursing Ethics. 2004;11(1):28-41.

82. Carrese J, Rhodes L. Western bioethics on the Navaho reservation: benefit or harm? JAMA. 1995;274:826-829.

83. Rashad AM, MacVane Phipps F, Haith-Cooper M. Obtaining informed consent in an Egyptian research study. Nursing Ethics. 2004;11(4):394-399.

84. Yick A, Berthold SM. Conducting research on violence in Asian American communities: methodological issues. Violence and Victims. 2005;20(6):661-677.

85. Washington State Legislature. Washington Administrative Code Chapter 246-100 Communicable and Certain Other Diseases. Available at http://apps.leg.wa.gov/wac/default.aspx?cite=246-100. Last accessed March 3, 2017.

86. King County. Summary of Washington State HIV/AIDS Reporting Requirements and Regulations. Available at http://www.kingcounty.gov/depts/health/communicable-diseases/hiv-std/patients/epidemiology/hiv-reporting-requirements.aspx. Last accessed March 3, 2017.

87. Centers for Disease Control and Prevention. Syringe Disinfection for Injection Drug Users. Available at https://npin.cdc.gov/publication/syringe-disinfection-injection-drug-users. Last accessed March 6, 2017.

88. U.S. Department of Health and Human Services, Health Resources and Services Administration. Guide for HIV/AIDS Clinical Care: 2014 Edition. Rockville, MD: U.S. Department of Health and Human Services, 2014.

89. U.S. Department of Health and Human Services. HIV Vaccine Development. Available at https://www.niaid.nih.gov/diseases-conditions/hiv-vaccine-development. Last accessed March 6, 2017.

90. Centers for Disease Control and Prevention. HIV/AIDS Prevention Research Synthesis Project. Available at https://www.cdc.gov/hiv/dhap/prb/prs. Last accessed March 6, 2017.

91. Washington State Legislature. Washington Administrative Code Chapter 246-101 Notifiable Conditions. Available at http://apps.leg.wa.gov/WAC/default.aspx?cite=246-101. Last accessed March 6, 2017.

Evidence-Based Practice Recommendations Citations

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Bethesda, MD: Department of Health and Human Services; 2016. Available at https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Last accessed March 10, 2017.


Copyright © 2017 NetCE, P.O. Box 997571, Sacramento, CA 95899-7571
Mention of commercial products does not indicate endorsement.